semaglutide linked to cancer Can obesity meds also reduce risk? A retrospective study of 1.1M patients found GLP-1 drugs, especially semaglutide, significantly lower risks for multiple cancers. But not all were equale: liraglutide was Full article: The multifaceted effects
Description
In these trials, liraglutide is administered subcutaneously and is typically administered once daily, with dosages ranging from 0.6mg to 1.8mg for type 2 diabetes and 3.0mg for overweight or obesity [16, 27]
If this continues we may even start using muscle and bone as fuel
:max_bytes(150000):strip_icc()/VWHealth-Could-GLP-1Drugs-Reduce-Obesity-Related-Cancers-in-the-Future-3-7d602ab39c0448ddb00cd91b06be2a84.jpg)
This can provide flexibility but lacks the rigorous testing undergone by FDA-approved versions like Wegovy
Mol Cell Biol 23 : 79737981 Lawrence CB et al
Order refills at least two weeks before your current vial runs out
Always consult a licensed healthcare provider before beginning any peptide protocol
